Published in Diabetes Obes Metab on March 28, 2013
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care (2015) 4.64
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia (2013) 2.67
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract (2013) 2.09
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab (2014) 1.99
Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care (2014) 1.79
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res (2015) 1.73
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One (2014) 1.60
Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon. J Pharmacol Pharmacother (2014) 1.40
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord (2014) 1.15
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther (2014) 1.14
A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes Metab J (2014) 1.14
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol (2014) 1.12
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab (2015) 1.03
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab (2016) 1.01
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia (2014) 1.00
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol (2014) 0.99
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther (2013) 0.98
Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens (2016) 0.95
Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One (2014) 0.94
Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord (2013) 0.92
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol (2016) 0.90
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. J Am Soc Nephrol (2016) 0.90
Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J Endocrinol Metab (2013) 0.89
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context (2014) 0.89
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clin Diabetes (2014) 0.87
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. J Clin Endocrinol Metab (2015) 0.87
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Ther (2015) 0.86
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) (2013) 0.86
Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin North Am (2013) 0.86
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes (2015) 0.85
Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement. Indian J Endocrinol Metab (2017) 0.85
Optimal therapy of type 2 diabetes: a controversial challenge. Aging (Albany NY) (2014) 0.85
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res (2014) 0.84
Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Renal Physiol (2016) 0.83
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol (2015) 0.83
Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes (2014) 0.82
Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. J Am Geriatr Soc (2016) 0.82
New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits (2014) 0.81
Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment. Clin Drug Investig (2014) 0.81
Clinical implications of canagliflozin treatment in patients with type 2 diabetes. Clin Diabetes (2015) 0.80
Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. Ther Adv Endocrinol Metab (2014) 0.80
The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract (2015) 0.79
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context (2014) 0.79
Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. ScientificWorldJournal (2015) 0.79
Update on the treatment of type 2 diabetes mellitus. World J Diabetes (2016) 0.79
Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes. Clin Diabetes (2014) 0.79
Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options. Ther Clin Risk Manag (2015) 0.78
Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes. Endocrinol Metab (Seoul) (2016) 0.78
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus. N Am J Med Sci (2014) 0.78
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab (2015) 0.78
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab (2016) 0.78
Canagliflozin: a novel treatment option for type 2 diabetes. Drug Des Devel Ther (2013) 0.77
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. Adv Ther (2016) 0.77
Canagliflozin. Hosp Pharm (2013) 0.77
Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats. Physiol Rep (2015) 0.77
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol (2016) 0.77
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med (2015) 0.76
Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Indian J Endocrinol Metab (2015) 0.76
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Indian J Endocrinol Metab (2016) 0.76
Emerging treatments in type 2 diabetes: focus on canagliflozin. Ther Clin Risk Manag (2014) 0.76
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol (2016) 0.76
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Adv Ther (2016) 0.75
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. Int J Clin Pract (2016) 0.75
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacol Toxicol (2017) 0.75
Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Metab Syndr Obes (2017) 0.75
Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Ther (2017) 0.75
An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. Vasc Health Risk Manag (2017) 0.75
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol (2017) 0.75
The renal effects of SGLT2 inhibitors and a mini-review of the literature. Ther Adv Endocrinol Metab (2016) 0.75
Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study. J Clin Med Res (2016) 0.75
Cystatin C- and Creatinine-Based Estimates of Glomerular Filtration Rate in Dapagliflozin Phase 3 Clinical Trials. Diabetes Ther (2016) 0.75
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Des Devel Ther (2014) 0.75
Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin. Br J Clin Pharmacol (2017) 0.75
Short commentary on empagliflozin and its potential clinical impact. Ther Adv Endocrinol Metab (2015) 0.75
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. Clin J Am Soc Nephrol (2017) 0.75
Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes Ther (2016) 0.75
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. J Am Soc Nephrol (2017) 0.75
Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. Int J Clin Pract (2017) 0.75
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy (2017) 0.75
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem (2007) 13.80
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 7.07
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med (2012) 3.38
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care (2012) 3.28
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab (2007) 3.06
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab (2011) 3.00
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab (2011) 2.77
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab (2012) 2.19
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem (2010) 2.03
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One (2012) 2.01
Screening for kidney disease in adults with diabetes. Diabetes Care (2005) 1.53
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol (2013) 0.99
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab (2013) 3.88
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab (2007) 3.44
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia (2013) 2.67
Molecular mechanisms of biocatalytic desulfurization of fossil fuels. Nat Biotechnol (1996) 2.27
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract (2013) 2.09
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab (2014) 1.99
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med (2013) 1.84
Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med (1996) 1.79
Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet (2000) 1.67
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int (2000) 1.66
Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res (1997) 1.54
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab (2014) 1.36
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin (2012) 1.30
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab (2015) 1.30
Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother (2002) 1.29
Increased translocations and aneusomy in chromosomes 8 and 21 among workers exposed to benzene. Cancer Res (1998) 1.28
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab (2014) 1.18
Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res (2000) 1.15
Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst (1999) 1.13
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology (1999) 1.10
Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res (1996) 1.08
Fonsecaea nubica sp. nov, a new agent of human chromoblastomycosis revealed using molecular data. Med Mycol (2010) 1.05
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab (2012) 1.05
Antitumor activities of the four sesquiterpene lactones from Elephantopus scaber L. Exp Oncol (2006) 1.05
Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. Diabetologia (2013) 1.03
N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation (2008) 1.02
Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: evidence from gene-knockout mice. Circulation (2000) 1.02
Traditional Chinese medicines improve the course of refractory leukemic lymphoblastic lymphoma and acute lymphocytic leukemia: two case reports. Am J Chin Med (1995) 1.01
Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene (1998) 0.97
Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice. Diabetologia (2011) 0.96
Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene (2010) 0.96
Fulminant type 1 diabetes in Caucasians: A report of three cases. Diabetes Metab (2008) 0.96
Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis (2010) 0.96
Low birth weight is associated with chronic kidney disease only in men. Kidney Int (2007) 0.95
HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (1995) 0.95
Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet (1994) 0.95
Apnoea following normocapnic mechanical ventilation in awake mammals: a demonstration of control system inertia. J Physiol (1993) 0.94
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab (2014) 0.93
Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells. Cell Death Differ (2010) 0.92
Strong family history predicts a younger age of onset for subjects diagnosed with type 2 diabetes. Diabetes Obes Metab (2004) 0.91
Effect of nucleoside modifications on the structure and thermal stability of Escherichia coli valine tRNA. Biochimie (1994) 0.91
Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab (2011) 0.91
A volume-dependent apneic threshold during NREM sleep in the dog. J Appl Physiol (1985) (1994) 0.91
Genotoxic markers among butadiene polymer workers in China. Carcinogenesis (2000) 0.90
Identification of candidate target genes for EVI-1, a zinc finger oncoprotein, using a novel selection strategy. Oncogene (1998) 0.90
Attenuation of massive cytokine response to the staphylococcal enterotoxin B superantigen by the innate immunomodulatory protein lactoferrin. Clin Exp Immunol (2009) 0.89
Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis (2011) 0.89
Synthetase recognition determinants of E. coli valine transfer RNA. Biochemistry (1999) 0.89
The mouse SCA2 gene: cDNA sequence, alternative splicing and protein expression. Hum Mol Genet (1998) 0.89
Neural-mechanical coupling of breathing in REM sleep. J Appl Physiol (1985) (1997) 0.88
Benzene increases aneuploidy in the lymphocytes of exposed workers: a comparison of data obtained by fluorescence in situ hybridization in interphase and metaphase cells. Environ Mol Mutagen (1999) 0.88
Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chemother (2004) 0.88
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab (2015) 0.87
T lymphocyte surface antigen markers in osteoporosis. J Bone Miner Res (1990) 0.87
Effects of lorazepam on fear-potentiated startle responses in man. J Psychopharmacol (2005) 0.87
De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival. Transplant Proc (2012) 0.87
Mitogen-activated protein kinases mediate heat shock-induced delayed protection in mouse heart. Am J Physiol Heart Circ Physiol (2001) 0.86
High frequency of nonsense mutations in the NF2 gene caused by C to T transitions in five CGA codons. Hum Mol Genet (1995) 0.86
Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies. Transplant Proc (2004) 0.86
Markers for carcinogenicity among butadiene-polymer workers in China. Chem Biol Interact (2001) 0.86
Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. DNA Cell Biol (1996) 0.85
Sequence and antigenic diversity in two immunodominant regions of the L2 protein of human papillomavirus types 6 and 16. J Infect Dis (1993) 0.85
hprt mutation frequency among workers exposed to 1,3-butadiene in China. Toxicology (1996) 0.85
Characterization of an EPSP-like potential recorded remotely from the round window. J Acoust Soc Am (1989) 0.85
Reproducibility and symptomatic predictors of a slow nutrient drinking test in health and in functional dyspepsia. Neurogastroenterol Motil (2008) 0.85
Functional consequences of site-directed mutation of conserved histidyl residues of the bacterial luciferase alpha subunit. Biochemistry (1991) 0.85
Prognostic significance of TMPRSS4 in gastric cancer. Neoplasma (2014) 0.85
Effect of omeprazole-induced hypergastrinaemia on the proliferation of colonic mucosal epithelial cells in the rat. Exp Clin Endocrinol (1991) 0.85
Evaluation of the vaccination status in pediatric renal transplant recipients. Pediatr Transplant (2008) 0.85
The effect of season on spermatozoa motility, plasma membrane and acrosome integrity in fresh and frozen-thawed semen from Xinong Saanen bucks. Reprod Domest Anim (2014) 0.85
Impact of maternal lifestyle factors on newborn HPRT mutant frequencies and molecular spectrum--initial results from the Prenatal Exposures and Preeclampsia Prevention (PEPP) Study. Mutat Res (1999) 0.84
Hypertension in patients with diabetes. Overcoming barriers to effective control. Postgrad Med (2000) 0.84
Genotype distributions of hepatitis C virus in São Paulo, Brazil: rare subtype found. Hepatology (1999) 0.83
Quantification of illegitimate V(D)J recombinase-mediated mutations in lymphocytes of newborns and adults. Mutat Res (1999) 0.83
New evidence for the genomic tag hypothesis: archaeal CCA-adding enzymes and tDNA substrates. Biol Bull (1999) 0.83
Crocetin improves the insulin resistance induced by high-fat diet in rats. Br J Pharmacol (2008) 0.82
Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int (1994) 0.82
Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. Clin Pharmacol Ther (2011) 0.82
A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil (2009) 0.82
Diabetic retinopathy and nephropathy in Fiji: comparison with data from an Australian diabetes centre. Aust N Z J Ophthalmol (1999) 0.82
[Bilateral pheochromocytoma. Genetics and treatment]. Ann Chir (2005) 0.82
Improvement of adynamic bone disease after renal transplantation. Braz J Med Biol Res (2005) 0.82
A high-resolution PAC and BAC map of the SCA2 region. Genomics (1997) 0.82
World Kidney Day: hypertension and chronic kidney disease. Lancet (2009) 0.81
Homozygosity for a 4-bp deletion in a patient with Wolfram syndrome suggesting possible phenotype and genotype correlation. Clin Genet (2001) 0.81
Dietary copper effects on lipid metabolism and circulating catecholamine concentrations in finishing steers. J Anim Sci (2000) 0.81
High-performance liquid chromatography (HPLC) determination of inosine, a potential biomarker for initial cardiac ischaemia, using isolated mouse hearts. Biomarkers (2006) 0.80
CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Diabetes Obes Metab (2014) 0.80
Effects of alpha-lipoic acid supplementation on antioxidative ability and performance of sows and nursing piglets. J Anim Physiol Anim Nutr (Berl) (2011) 0.80